about
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsRisk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsElderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of DigestiveEfficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastomaEpidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associationsChemotherapy for advanced gastric cancer: across the years for a standard of care.Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.Locally advanced rectal cancer: the importance of a multidisciplinary approach.Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patientsMolecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches.Pre-operative treatment modalities in gastric cancer patients.Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.New target therapies in advanced pancreatic cancer.The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients.A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.Pancreatic cancer: progress in cancer therapy.Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinomaWomen and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapyRisk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1.Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2.Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.5-Fluorouracil pharmacogenomics: still rocking after all these years?Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity.Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review.Essential role of Gli proteins in glioblastoma multiforme.
P50
Q24297784-50297DCA-7966-40D0-B99B-151DA376DE88Q26822790-4B490D11-A626-4165-9064-28CB8ED39DF6Q28551983-7D645C3A-B939-425E-B11C-86B8FBAE911EQ33357939-F4E3B9AA-D45A-42AA-A395-EF8C26A8A7B2Q33360403-2EB16CF8-6A3F-4BF7-A92C-A322C9CDC83DQ33406919-33F43F4E-047D-4647-9E43-5DC2F6296DB3Q33497634-F59067C5-6186-4577-967C-233F9A2E04CDQ34309894-9A73D351-1D97-40F1-AF3B-ED7650F5E51BQ34617795-D9CDEC3E-277D-44A9-AE66-2091C30AFA1AQ34660799-9D661379-240C-4026-A1B4-B4C4678E0051Q34696515-93336D69-56C7-4E72-B020-BFE49884F342Q35034474-E54202D5-3BB4-4F1C-8BDA-B5EB64665F40Q35080143-A9ED123C-7093-44DD-85B4-95F23435E22CQ35083485-4D08480A-4B87-4D7A-849D-B95C1153DCECQ35577964-9DC9AFE2-4169-4727-A630-577768C262FEQ35584314-890570C5-4852-476B-8875-50D79D315110Q35595696-25FA76B1-84A3-451E-9541-3181CA09946FQ35832110-8F94F4CC-BDD1-4958-B1A6-31871D88A1B5Q36143651-0BEA809A-58E8-4DB8-AFF6-0A8FD6A078B2Q36425973-B10D2E3E-83C2-49B7-9C7B-7BF672E769F8Q36522711-AB74B1DF-88DC-450B-BB7F-BED7BA5AA28CQ36544310-6B3C9B3B-DE5A-414A-BA6F-5FCBE5FE6B55Q36608628-C5AE5B44-009A-46E0-AADE-7FD70FAC0179Q36616487-AC7AD10B-B260-4429-83AC-CE57E30CE1BDQ37049110-22CB1C8C-761D-4D35-AE67-829674E565E2Q37115068-AE6F94BE-93EC-4A7E-AE94-439889F69B24Q37214300-05B6F0B8-E480-45A4-BFFC-0072FF4796F1Q37250383-89345DAD-A4AD-4045-B747-1FF471891E67Q37295840-28020F77-70E0-492A-98BC-C01C413AB6DAQ37362945-3EF480B1-5766-44BB-9275-8276E82ABF48Q37495094-E1FD2C2E-1DFF-49E5-9F87-7005B4E3A647Q37565629-2F206732-6A8C-4FE9-B9F0-94161C22FB68Q37598888-04A58F42-5AE9-4BE1-A01C-52AE19F68C53Q37678516-D3394F7A-86C9-480C-BB17-C432D38FCB75Q37783666-77C450F2-4C08-4163-BF15-0B5993AD1BA5Q37844550-88ED41C7-5238-4707-8EC5-125B3666FD70Q38013163-D0E285C3-D2C9-4B29-B0E6-7F6E23F89E66Q38063351-506C0D94-9FD2-4AC3-973A-B104816BFA02Q38092387-9C490FF5-6711-45B5-A2F1-E1F8E559428BQ38094725-CC8B41A1-937F-4557-8849-E1E52D29565D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rossana Berardi
@ast
Rossana Berardi
@en
Rossana Berardi
@es
Rossana Berardi
@nl
Rossana Berardi
@sl
type
label
Rossana Berardi
@ast
Rossana Berardi
@en
Rossana Berardi
@es
Rossana Berardi
@nl
Rossana Berardi
@sl
prefLabel
Rossana Berardi
@ast
Rossana Berardi
@en
Rossana Berardi
@es
Rossana Berardi
@nl
Rossana Berardi
@sl
P106
P1153
7103074468
P21
P31
P496
0000-0002-9529-2960